NorthWest Biotherapeutics Inc (NWBO)

[Just1guy]

I don’t recall what the EU trial said before. This seems strange to me.

“ The primary endpoint of this study is overall survival (OS) compared between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in patients with newly diagnosed glioblastoma.”

Has it always been they will compare OS treatment group to control groups that received SOC in different trials?

The second through fifth Secondary endpoints specifically compare the treatment to control group within this study.

“The second secondary endpoint, confirmed progression-free survival (cPFS), is confirmed disease progression (cPD) compared between subjects randomized to DCVax®-L and those randomized to Placebo within Study 020221.”

Regards